FDA seeks treatment protocol for Protalix Gaucher's disease drug

07/6/2009 | Wall Street Journal, The

The FDA asked Protalix to submit a treatment protocol for prGCD, its experimental Gaucher's disease drug, in light of a manufacturing problem that is expected to reduce the supply of Genzyme's Cerezyme. Protalix and the agency are reportedly discussing parameters to increase patients' access to prGCD.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY